NEW YORK (GenomeWeb News) — Tripos today said it plans to sell its Discovery Research business to Provid Pharmaceuticals in a stock sale worth roughly $2 million.
That price may change, depending on changes in capital, debts, equipment, and facility values, Tripos said. The deal also hinges on Provid’s ability to secure the necessary financing, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.